Company profile: Intershunt
1.1 - Company Overview
Company description
- Provider of a catheter-based, minimally invasive percutaneous atrial shunt system designed to relieve left atrial pressure and improve breathing in heart failure patients; currently under development.
Products and services
- Catheter-Based Atrial Shunt Approach: Develops catheter-based shunt relieving left atrial pressure to enhance breathing in heart failure patients, minimally-invasive
- InterShunt Percutaneous Atrial Shunt Catheter System: Catheter-based percutaneous system reducing left atrial pressure to improve breathing in heart failure, currently under development
- Minimally-Invasive Catheter Procedure Development: Engineers minimally-invasive procedure relieving heart failure by lowering left atrial pressure and improving breathing for patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Intershunt
Perouse Medical
HQ: France
Website
- Description: Provider of medical devices for the treatment of cardiovascular pathologies and for vascular access for intravenous therapies, specializing in long-term vascular access; part of the Vygon Group, a French group specialized in single-use medical devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perouse Medical company profile →
GB Sciences
HQ: United States
Website
- Description: Provider of research and biotechnical development focused on plant-based therapeutics, including the PhAROS AI drug discovery platform to identify and predict active ingredients; therapies for Parkinson’s disease (animal proof-of-concept, US patent); COVID-related cytokine release syndrome therapies (positive proof-of-concept); and oral nanoparticle pain therapeutics (US patent, ongoing animal studies).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GB Sciences company profile →
NitroMed
HQ: United States
Website
- Description: Provider of proprietary nitric oxide-based pharmaceuticals, leveraging substantial expertise and intellectual property in nitric oxide drug development. The company discovers, develops, and seeks to commercialize therapies based on the therapeutic benefits of nitric oxide and is conducting a late-stage confirmatory trial of its lead nitric oxide-enhancing drug, BiDil.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NitroMed company profile →
Nellix
HQ: United States
Website
- Description: Provider of medical devices for minimally invasive treatment of aortic aneurysms, including abdominal (AAA) and thoracic (TAA), featuring an original device with a low-profile delivery system and innovative endograft designed to expand indications for less invasive care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nellix company profile →
Cardiol Therapeutics
HQ: Canada
Website
- Description: Provider of cannabidiol-based therapies for heart disease, including CardiolRx, an oral solution in clinical development to inhibit inflammatory pathways; CRD-38, a subcutaneous formulation for heart failure aiming to improve pharmacokinetics and therapeutic efficacy; and Phase II studies MAvERIC-Pilot (recurrent pericarditis) and ARCHER (acute myocarditis) evaluating safety, tolerability, efficacy, and impact on myocardial recovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardiol Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Intershunt
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Intershunt
2.2 - Growth funds investing in similar companies to Intershunt
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Intershunt
4.2 - Public trading comparable groups for Intershunt
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →